Actavis receives approval of generic Wellbutrin in U.S.

Editorial Checklist Reviewed
Aug 18 2008NewsGuard 100/100 Score

Actavis Group today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder. Annual US sales of brand and generic Wellbutrin XL 300mg were US$581 million for the 12 months ending June 2008 according to IMS Health data.

Commenting on the new approval, Douglas Boothe, Chief Executive Officer of Actavis, Inc. said:

"Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group's focus and expertise in bringing complex controlled-release technologies to the marketplace."

Source:

http://www.actavis.com

Posted in: Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

Six common flying with food allergies myths
Key triggers for food allergies in children after organ transplants
Ultra-processed food linked to weight gain and lower well-being in adolescents
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Living in food deserts during early childhood raises long-term obesity risk
Limiting fast-food outlets can reduce childhood overweight and obesity

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Frequent ultra-processed food consumption raises mortality risks, especially in women